Peregrine's Bavituximab Results Similar To Placebo

Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) reported positive results from a Phase II clinical trial of bavituximab for treating patients with Stage IV pancreatic cancer but TheStreet said that the results were the same as a placebo sending the stock price downy 42 cents to close at $1.69.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here